Fluorometholone ophthalmic Alternatives Compared
| Fluorometholone ophthalmic | Lumify (brimonidine) | Naphazoline ophthalmic |
|
|---|
| Fluorometholone ophthalmic | Lumify (brimonidine) | Naphazoline ophthalmic |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Eyelash Hypotrichosis, Eye Redness/Itching, Steroid Responsive Inflammatory Conditions, Eye Redness, Allergies. Fluorometholone ophthalmic may also be used for purposes not listed in... View more |
Over-the-counter
Prescribed for Eye Redness. Lumify may also be used for purposes not listed in this medication guide. |
Prescription and OTC
Prescribed for Eye Redness. Naphazoline ophthalmic may also be used for purposes not listed in this medication guide. |
Related suggestions Eye Redness
|
|||||||||||||||
| More about Fluorometholone ophthalmic | More about Lumify (brimonidine) | More about Naphazoline ophthalmic | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Fluorometholone ophthalmic has an average rating of 6.3 out of 10 from a total of 11 ratings on Drugs.com. 45% of reviewers reported a positive effect, while 27% reported a negative effect. |
Lumify has an average rating of 3.2 out of 10 from a total of 175 ratings on Drugs.com. 19% of reviewers reported a positive effect, while 73% reported a negative effect. |
Naphazoline ophthalmic has an average rating of 3.3 out of 10 from a total of 4 ratings on Drugs.com. 25% of reviewers reported a positive effect, while 75% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
View all Lumify side effects |
View all Naphazoline ophthalmic side effects |
|||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
Lower cost generic |
Lower cost generic approved |
Lower cost generic |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Fluorometholone ophthalmic prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Naphazoline ophthalmic prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Eflone, Flarex, FML, FML Forte Liquifilm, FML Liquifilm, FML S.O.P. | Other brimonidine brands include: Alphagan P, Lumify Preservative Free, Qoliana | Advanced Eye Relief, AK-Con, All Clear, All Clear AR, Allerest Eye Drops, Allersol, Clear Eyes Maximum Redness Relief, Clear Eyes Redness Relief, Degest 2, Estivin II, GoodSense Redness Relief Plus, Naphcon, Nazil Ofteno, Vasocon View more | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
|
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 42 drugs are known to interact with Fluorometholone ophthalmic:
|
A total of 369 drugs are known to interact with Lumify:
|
A total of 49 drugs are known to interact with Naphazoline ophthalmic:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
December 22, 2017 |
N/A |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.